ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 42

Resveratrol Regulates Sirt1 to Control B Cells Activation and Plasma B Cells Differentiation

Ting Wang1, Xing Song2, Xiaofang Luo2, Mengtao Li2 and Xiaofeng Zeng1, 1Rheumatology, Peking Union Medical College and Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing, China, 2Peking Union Medical College and Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing, China

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: ,

Session Information

Date: Sunday, November 5, 2017

Title: B Cell Biology and Targets in Autoimmune Disease Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-systemic autoimmune disease characterized by B cell hyperactivation and the production of autoantibodies. Histone deacetylase, Sirtuin1 (Sirt1) has been shown to play a role in regulation of inflammation. Sirt1 deficiency results in the development of lupus-like disease in mice, including the production of anti-nuclear antibody.Resveratrol (trans-3,4′,5-trihydroxystilbene), a natural polyphenolic phytoalexins, is a potent activator of Sirt1. Our study was conducted to determine the expression of Sirt1 in B cells in SLE patients and further test the effects of resveratrol on B cell activation and auto-Ab production in pristane-induced mouse lupus model.

Methods: Flow cytometry and real-time PCR were used to analyze the expression of Sirt1. Sirt1 signaling was modulated with the Sirt1 agonist resveratrol. BALB/c mice were given 0.5 ml of pristane on day 1 by intraperitoneal injection to induce the lupus-like disease and on day 2 the mice received various doses of resveratrol. CD19+ B cells were isolated from the spleen mononuclear cells of the pristane-induced lupus mice and cultured with or without resveratrol in vitro for 3-5 days and B cell activation, plasma B cell differentiation and Prdm1 gene expression were assessed by flow cytometry or real-time PCR.

Results: The expression of Sirt1 in CD19+B cells of SLE patients was significantly decreased when compared to healthy donors (p=0.0071). The expression of Sirt1 negatively correlated with CD19+ B cell frequencies (p=0.0008). In pristane-induced lupus mice, Sirt1 activator-resveratrol dramatically decreased the expression of CD69, CD80, CD86 expression of B lymphocytes in a dose-dependent manner. Resveratrol significantly inhibited CDl38+ plasma cell differentiation of B lymphocytes after stimulation with LPS plus anti-CD40 antibody. Finally, resveratrol significantly inhibited the expression of PRDM1(gene encoding Blimp-1) mRNA in B-cells.

Conclusion: Sirt1 is downregulated in SLE patients. The use of resveratrol, Sirt1 agonist may present a novel approach for treatment of SLE by inhibiting B cell activation and plasma cell differentiation.

Disclosure: T. Wang, None; X. Song, None; X. Luo, None; M. Li, None; X. Zeng, None.

To cite this abstract in AMA style:

Wang T, Song X, Luo X, Li M, Zeng X. Resveratrol Regulates Sirt1 to Control B Cells Activation and Plasma B Cells Differentiation [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/resveratrol-regulates-sirt1-to-control-b-cells-activation-and-plasma-b-cells-differentiation/. Accessed .

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/resveratrol-regulates-sirt1-to-control-b-cells-activation-and-plasma-b-cells-differentiation/